Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q1 FY25 results · Apr–Jun 2024
Jubilant Pharmova reported revenue from operations of ₹1,731.70 crore (up 9.1% from Q1 FY24) and net profit of ₹481.80 crore (up 7930.0% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,731.70 | 1,586.90 | +9.1% | 175.86 | +884.7% |
| Other income | 14.00 | 8.60 | +62.8% | 1.44 | +872.2% |
| Total income | 1,745.70 | 1,595.50 | +9.4% | 177.30 | +884.6% |
| Profit before tax | 499.70 | 26.60 | 19x | (5.71) | Turned profit |
| Net profit for the period | 481.80 | 6.00 | 80x | (6.18) | Turned profit |
| Attributable to shareholders of the company | 482.10 | 6.40 | 75x | (5.86) | Turned profit |
| EPS, basic (₹) | 30.44 | 0.40 | 76x | (3.69) | not comparable |
| Net margin (%) | 27.8 | 0.4 | -3.5 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 166.70 | 217.40 | −23.3% | 205.80 | −19.0% |
| Other income | 19.50 | 15.90 | +22.6% | 50.10 | −61.1% |
| Total income | 186.20 | 233.30 | −20.2% | 255.90 | −27.2% |
| Profit before tax | (11.20) | 2.30 | Turned loss | 41.50 | Turned loss |
| Net profit for the period | (10.20) | 1.90 | Turned loss | 32.50 | Turned loss |
| EPS, basic (₹) | (0.64) | 0.12 | Turned loss | 2.05 | Turned loss |
| Net margin (%) | -6.1 | 0.9 | 15.8 |
Consolidated
- Filed with BSE
- 20 Jul 2024, 15:05 IST
- Board meeting
- 19 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Jul 2024, 15:05 IST
- Board meeting
- 19 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE